Commercial Test for BRAF Gene Available

Clarient Inc. announced the launch of a commercially available test for the BRAF mutation in colorectal cancer. The test detects mutations in colorectal cancer tumor tissue. In a recent study, patients with mutated BRAF did not respond to treatment with two drugs that block epidermal growth factor receptors (EGFR) — Erbitux® (cetuximab) and Vectibix™ (panitumumab). Patients… Read More